CN107875288A - 具有活血、美容功效的中药组合物及其颗粒剂的制备方法 - Google Patents
具有活血、美容功效的中药组合物及其颗粒剂的制备方法 Download PDFInfo
- Publication number
- CN107875288A CN107875288A CN201711237245.6A CN201711237245A CN107875288A CN 107875288 A CN107875288 A CN 107875288A CN 201711237245 A CN201711237245 A CN 201711237245A CN 107875288 A CN107875288 A CN 107875288A
- Authority
- CN
- China
- Prior art keywords
- blood circulation
- promoting blood
- preparation
- beauty functions
- chinese medicinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 58
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 230000001737 promoting effect Effects 0.000 title claims abstract description 32
- 230000017531 blood circulation Effects 0.000 title claims abstract description 31
- 230000006870 function Effects 0.000 title claims abstract description 26
- 230000003796 beauty Effects 0.000 title claims abstract description 24
- 239000008187 granular material Substances 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims description 17
- 241000255789 Bombyx mori Species 0.000 claims abstract description 21
- 244000144725 Amygdalus communis Species 0.000 claims abstract description 18
- 235000011437 Amygdalus communis Nutrition 0.000 claims abstract description 18
- 241001313855 Bletilla Species 0.000 claims abstract description 18
- 235000020224 almond Nutrition 0.000 claims abstract description 18
- 210000000582 semen Anatomy 0.000 claims abstract description 18
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 17
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 17
- 244000284380 Hibiscus rosa sinensis Species 0.000 claims abstract description 17
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 17
- 235000005412 red sage Nutrition 0.000 claims abstract description 17
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 16
- 235000000100 Hibiscus rosa sinensis Nutrition 0.000 claims abstract description 16
- 235000000664 Rosa chinensis Nutrition 0.000 claims abstract description 16
- 235000016785 Rosa della China Nutrition 0.000 claims abstract description 16
- 244000223014 Syzygium aromaticum Species 0.000 claims abstract description 16
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims abstract description 16
- 238000000605 extraction Methods 0.000 claims abstract description 14
- 241000405414 Rehmannia Species 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 244000061520 Angelica archangelica Species 0.000 claims abstract 4
- 239000006071 cream Substances 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 42
- 239000000843 powder Substances 0.000 claims description 40
- 239000000463 material Substances 0.000 claims description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 238000001035 drying Methods 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 238000001291 vacuum drying Methods 0.000 claims description 11
- 238000007873 sieving Methods 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 235000020985 whole grains Nutrition 0.000 claims description 9
- 239000005913 Maltodextrin Substances 0.000 claims description 8
- 229920002774 Maltodextrin Polymers 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 229940035034 maltodextrin Drugs 0.000 claims description 8
- 238000003860 storage Methods 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 239000007921 spray Substances 0.000 claims description 7
- 239000000853 adhesive Substances 0.000 claims description 6
- 230000001070 adhesive effect Effects 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 238000011282 treatment Methods 0.000 abstract description 34
- 239000008280 blood Substances 0.000 abstract description 16
- 210000004369 blood Anatomy 0.000 abstract description 16
- 201000010099 disease Diseases 0.000 abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 12
- 230000003712 anti-aging effect Effects 0.000 abstract description 8
- 230000032683 aging Effects 0.000 abstract description 7
- 238000011160 research Methods 0.000 abstract description 6
- 206010042496 Sunburn Diseases 0.000 abstract description 4
- 230000004087 circulation Effects 0.000 abstract description 4
- 230000001815 facial effect Effects 0.000 abstract description 4
- 230000009467 reduction Effects 0.000 abstract description 3
- 230000002087 whitening effect Effects 0.000 abstract description 3
- 206010001497 Agitation Diseases 0.000 abstract description 2
- 239000003963 antioxidant agent Substances 0.000 abstract description 2
- 230000003078 antioxidant effect Effects 0.000 abstract description 2
- 235000006708 antioxidants Nutrition 0.000 abstract description 2
- 230000006378 damage Effects 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract description 2
- 238000012545 processing Methods 0.000 abstract description 2
- 230000002936 tranquilizing effect Effects 0.000 abstract description 2
- 230000000857 drug effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 239000002245 particle Substances 0.000 description 16
- 241000125175 Angelica Species 0.000 description 12
- 238000010438 heat treatment Methods 0.000 description 8
- 208000003351 Melanosis Diseases 0.000 description 7
- 206010008570 Chloasma Diseases 0.000 description 6
- 206010013786 Dry skin Diseases 0.000 description 6
- 206010040882 skin lesion Diseases 0.000 description 6
- 231100000444 skin lesion Toxicity 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000011122 softwood Substances 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- -1 2 furan steroid alkene Chemical class 0.000 description 2
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- SCCDQYPEOIRVGX-UHFFFAOYSA-N Acetyleugenol Chemical compound COC1=CC(CC=C)=CC=C1OC(C)=O SCCDQYPEOIRVGX-UHFFFAOYSA-N 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241001481296 Malus spectabilis Species 0.000 description 2
- 208000037093 Menstruation Disturbances Diseases 0.000 description 2
- 206010027339 Menstruation irregular Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- CATSNJVOTSVZJV-UHFFFAOYSA-N heptan-2-one Chemical compound CCCCCC(C)=O CATSNJVOTSVZJV-UHFFFAOYSA-N 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical group Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000015602 Actinic lichen planus Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 241000255783 Bombycidae Species 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 description 1
- DYQVDISPPLTLLR-HJQYTNQXSA-N Carthamin Natural products CC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@]2(O)C(=C(C=C/3C(=O)C(=C(O)[C@](O)([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C3=O)C(=O)C=Cc5ccc(O)cc5)C(=O)C(=C2O)C(=O)C=Cc6ccc(O)cc6)O DYQVDISPPLTLLR-HJQYTNQXSA-N 0.000 description 1
- QIIDATRCGITYRZ-UHFFFAOYSA-N Catalpol Natural products OCC1OC(OC2OC=CC3C(O)C(=C(CO)C23)O)C(O)C(O)C1O QIIDATRCGITYRZ-UHFFFAOYSA-N 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- 240000003211 Corylus maxima Species 0.000 description 1
- PQMOXTJVIYEOQL-UHFFFAOYSA-N Cumarin Natural products CC(C)=CCC1=C(O)C(C(=O)C(C)CC)=C(O)C2=C1OC(=O)C=C2CCC PQMOXTJVIYEOQL-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 208000003367 Hypopigmentation Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- FSOGIJPGPZWNGO-UHFFFAOYSA-N Meomammein Natural products CCC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)C2=C1OC(=O)C=C2CCC FSOGIJPGPZWNGO-UHFFFAOYSA-N 0.000 description 1
- HMMCOAQTWLRBMU-WANIKOBHSA-N O1CC(C)CC[C@@]11C(=C)[C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CCCCC5CC[C@H]4[C@@H]3C[C@@H]2O1 Chemical compound O1CC(C)CC[C@@]11C(=C)[C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CCCCC5CC[C@H]4[C@@H]3C[C@@H]2O1 HMMCOAQTWLRBMU-WANIKOBHSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 206010041956 Stasis syndrome Diseases 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- VBIXEXWLHSRNKB-UHFFFAOYSA-N ammonium oxalate Chemical compound [NH4+].[NH4+].[O-]C(=O)C([O-])=O VBIXEXWLHSRNKB-UHFFFAOYSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000005634 blind loop syndrome Diseases 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- LHDWRKICQLTVDL-PZYDOOQISA-N catalpol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2C=CO1 LHDWRKICQLTVDL-PZYDOOQISA-N 0.000 description 1
- UXSACQOOWZMGSE-UHFFFAOYSA-N catalposide Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(OC(=O)C=3C=CC(O)=CC=3)C2C=CO1 UXSACQOOWZMGSE-UHFFFAOYSA-N 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000003425 hypopigmentation Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 238000009992 mercerising Methods 0.000 description 1
- LHDWRKICQLTVDL-UHFFFAOYSA-N methyl iridoid glycoside Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2C=CO1 LHDWRKICQLTVDL-UHFFFAOYSA-N 0.000 description 1
- 201000002266 mite infestation Diseases 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- GMFLGNRCCFYOKL-ACCCYTKYSA-N polypodine B Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@]21O GMFLGNRCCFYOKL-ACCCYTKYSA-N 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Insects & Arthropods (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种具有活血、美容功效的中药组合物,由生地、当归、红花、白芷、杏仁、丹参、菟丝子、黄精、白及、月季花、丁香、白僵蚕组成,各原料的质量百分比均为6.004%~10.00%,各组分的质量百分比之和为100%。本发明一种具有活血、美容功效的中药组合物,具有活血、行气、美白、改善面部血液循环、祛斑美容、提高免疫力、镇静安神,使面部兴奋性降低之药效,再经过高科技加工提取制成颗粒剂使用,药理学研究证明,其具有抗氧化、抗衰老、抗红血丝、抗日晒斑等多种功效。本发明中药组合物填补了现有中成药治疗衰老引起的损荣性疾病的市场空白。
Description
技术领域
本发明属于中药组合物技术领域,具体涉及一种具有活血、美容功效的中药组合物,本发明还涉及上述中药组合物颗粒剂的制备方法。
背景技术
从2008年开始,国际抗衰老化妆品与抗衰老保健食品及相关服务费支出合计高达1680亿美元,2011年这一数字已上升为近1900亿美元,年综合增长率高达12%。这为抗衰老美容产品行业提供了良好市场前景。
尽管延缓衰老的方法较多,但西药易产生耐受性,副作用大,使用后效果不好,没从根本上起到调理治疗的作用。中医认为,瘀血作为病理产物可致皮肤衰老。血瘀是促进人体衰老的重要原因之一,血瘀致肤衰老表现为甲瘀脉青、色素沉着、皮肤粗糙、老年斑等。瘀血内阻,气血运行不畅,使脏腑得不到正常濡养。人体正常生理功能就要发生障碍,从而加速人体衰老进程。因此,延缓血瘀证产生是防止早衰的关键。
中医对于衰老的认识自古有之,早在《黄帝内经》中对衰老就有了较为系统的论述。早期内经中从肾论治开始、到金元时期李杲的脾胃论治再到脾肺论治经过长期的探索和认识,使抗衰老理论有了不断的进步与发展;在临床运用补肾、补肾健脾活血、养血调肝、益气健脾祛痰化瘀等法用于抗衰的防治,使抗衰在治法上得到了不断的丰富与补充。而在中药方面的有关研究则从单味药研究、复方研究及化妆品研究等方向肯定了中药对衰老的防治作用。
发明内容
本发明的目的是提供一种具有活血、美容功效的中药组合物,填补了现有中成药治疗衰老引起的损荣性疾病的市场空白。
本发明的另一目的是提供上述中药组合物颗粒剂的制备方法。
本发明所采用的技术方案是,一种具有活血、美容功效的中药组合物,按照质量百分比由以下中药组成:生地6.004%~10.00%、当归6.004%~10.00%、红花6.004%~10.00%、白芷6.004%~10.00%、杏仁6.004%~10.00%、丹参6.004%~10.00%、菟丝子6.004%~10.00%、黄精6.004%~10.00%、白及6.004%~10.00%、月季花6.004%~10.00%、丁香6.004%~10.00%、白僵蚕6.004%~10.00%,各组分的质量百分比之和为100%。
本发明所采用的另一技术方案是,具有活血、美容功效的中药组合物颗粒剂的制备方法,具体按照以下步骤实施:
步骤1,分别称取生地、当归、红花、白芷、杏仁、丹参、菟丝子、黄精、白及、月季花、丁香、白僵蚕饮片;
步骤2,将步骤1称取的各原料饮片放入真空提取罐中,进行提取药液;
步骤3,将步骤2中提取的药液浓缩浸膏后,真空干燥,得到膏粉,并对膏粉进行粉碎过筛;
步骤4,将步骤3得到的膏粉放入高效湿法混合制粒机中,加入辅料,混合均匀,然后喷以粘合剂,搅拌、过筛、整粒、干燥,即得。
本发明的特点还在于,
步骤1中各原料饮片按照质量百分比分别为:地6.004%~10.00%、当归6.004%~10.00%、红花6.004%~10.00%、白芷6.004%~10.00%、杏仁6.004%~10.00%、丹参6.004%~10.00%、菟丝子6.004%~10.00%、黄精6.004%~10.00%、白及6.004%~10.00%、月季花6.004%~10.00%、丁香6.004%~10.00%、白僵蚕6.004%~10.00%,各组分的质量百分比之和为100%。
步骤2中提取过程具体为:将称取的饮片加入真空提取罐中,加水煎煮2次,滤过,滤液泵入药液贮罐,放置3h以上,取上清液滤过,即得药液。
2次煎煮具体为:第1次加饮片质量8倍的水,煎煮1.5~2h;第2次加饮片质量8倍的水,煎煮1~1.5h。
步骤3中,浓缩后浸膏的相对密度1.02~1.04。
步骤3中,真空干燥温度为80~85℃,干燥时间为50~60min;粉碎后过80目筛。
步骤4中膏粉与辅料的质量比为1:1~1.5,辅料由蔗糖和麦芽糊精按质量比1:1~1.5组成。
步骤4中酒精的质量浓度为85%~90%,酒精的用量为膏粉质量的15%~20%。
步骤4中搅拌过程中控制温度在48~55℃;干燥温度为55~60℃,干燥时间为1.5~2h。
本发明的有益效果是,本发明一种具有活血、美容功效的中药组合物,具有活血、行气、美白、改善面部血液循环、祛斑美容、提高免疫力、镇静安神,使面部兴奋性降低之药效,再经过高科技加工提取制成颗粒剂使用,药理学研究证明,其具有抗氧化、抗衰老、抗红血丝、抗日晒斑等多种功效。
具体实施方式
下面结合具体实施方式对本发明进行详细说明。
本发明一种具有活血、美容功效的中药组合物,按照质量百分比由以下中药组成:生地6.004%~10.00%、当归6.004%~10.00%、红花6.004%~10.00%、白芷6.004%~10.00%、杏仁6.004%~10.00%、丹参6.004%~10.00%、菟丝子6.004%~10.00%、黄精6.004%~10.00%、白及6.004%~10.00%、月季花6.004%~10.00%、丁香6.004%~10.00%、白僵蚕6.004%~10.00%,各组分的质量百分比之和为100%。
上述具有活血、美容功效的中药组合物颗粒剂的制备方法,具体按照以下步骤实施:
步骤1,称取原料饮片
按比例分别称取生地、当归、红花、白芷、杏仁、丹参、菟丝子、黄精、白及、月季花、丁香、白僵蚕。
步骤2,饮片煎煮提取
将称取的药材加入真空提取罐中,加水煎煮2次:第1次加饮片质量8倍的水,煎煮1.5~2h;第2次加饮片质量8倍的水,煎煮1~1.5h;药液滤过,滤液泵入药液贮罐,放置3h以上,取上清液滤过,得到提取液。
相比于通过传统煎煮提取的方式,本发明使用真空提取罐进行提取,避免有效成分的损失和流失,并且能够最大程度的保留原料提取液的有效成分含量。
步骤3,浓缩收膏、干燥
将提取液真空浓缩至相对密度1.02~1.04(80℃)浸膏,然后在真空干燥箱80~85℃,干燥50~60min,得到膏粉。
浓缩是使溶液中的溶媒蒸发、溶液浓度增大的过程。我们通过减压蒸发又称真空蒸发。减压蒸发是指在密闭容器内,通过抽真空的方式来降低液体表面压力,使液体低温沸腾蒸发的操作方法。
真空干燥箱,箱内被加热板分成若干层。加热板中通入热水或低压蒸汽作为加热介质,将铺有待干燥药品的料盘放在加热板上,关闭箱门,箱内用真空泵抽成真空。加热板在加热介质的循环流动中将药品加热到指定温度,水分即开始蒸发并随抽真空逐渐抽走。此设备易于控制,可冷凝回收被蒸发的溶媒,干燥过程中药品不易被污染,可以用在药品干燥、包材灭菌及热处理上。
步骤4,粉碎
将步骤3得到的膏粉粉碎过80目筛。
粉碎可减少粒径,增加比表面积,促进制剂中成分的混合均匀,有利于提高制剂质量。
步骤5,制粒
将步骤4粉碎后的膏粉放入高效湿法混合制粒机中,加入辅料,混合均匀,然后喷以酒精作为粘合剂,在48~55℃搅拌到手捏成团,触之即散时,过筛,整粒,放入烘箱中55~60℃干燥1.5~2h,即得。
其中膏粉与辅料的质量比为1:1~1.5,辅料由蔗糖和麦芽糊精按质量比1:1~1.5组成。酒精的质量浓度为85%~90%,酒精的用量为膏粉质量的15%~20%。
高效湿法混合制粒机的整个工作过程是由混合、制粒两个工序组成。(1)中药药材膏粉从锥形料斗上方进入物料锅,待料斗关闭后在混合桨的搅拌下,粉料在容器内作上下翻滚的旋转运动,同时物料又被搅拌桨的离心力作用沿锥形壁方向作运动变化,形成半流动的高效混和状态,物料被碰撞分散达到充分的混和。制粒时由于粘合剂的注入,使粉料逐渐湿润,物料性状发生变化,加强了桨叶和筒壁对物料的挤压、摩擦、捏合,在粘合剂的作用下,逐步生成液桥,物料逐步转变为疏松的软材。(2)这些团粒软材,经过切割刀部位时,在高速旋转的切割刀的切割、粉碎,软材在半流动的状态下,被切成细小、均匀的颗粒,实现物料的相互转化,开启料门,湿颗粒被推出料斗。设置搅拌速度为800rpm,切碎转速是600rpm,切碎功率0.75kW,下部出来的颗粒和细粉转移至摇摆式颗粒机内进行整粒,过60目筛,最后制得粒度在60目、色泽均匀的颗粒。
检测颗粒粒度偏差,结果如表1所示:从RSD分析,其3个批次的粒度之间偏差较小,且3个批次各自的粒度偏差都不超过15.0%,符合药典要求。
表1粒度结果表
检测批次间颗粒的水分含量,结果如表2所示:各批次活血美颗粒的水分都小于6%,符合药典中关于水平的规定,3个批次平均水分含量之间的RSD较小,说明颗粒的水分在各个批次之间相对稳定。
表2颗粒剂水分含量
检测颗粒的溶解性:颗粒在3min内全部溶解,仅在杯底出现少量浑浊,没有发现异物和焦炭的出现,表明该颗粒的溶解性良好,达到药典的相关要求。
综上,采用本发明方法制备的具有活血、美容功效的中药组合物颗粒剂:
1、粒度在药典规定的范围内,颗粒的粒度较均一。
2、颗粒属于可溶性颗粒,颗粒在3min内全部溶解,表明颗粒溶解性好。
3、颗粒水分均在规定的范围内,颗粒质量能够达到相关要求。
下面从原料方面说明本发明中药组合物原料选取的理由:
生地,主要含B-谷甾醇与甘露醇,及少量豆甾醇、微量的菜油甾醇,还含地黄素、生物碱、脂肪酸、梓醇、葡萄糖与0.0053%的维生素A类物质。具有清热凉血、益阴生津之功效。用于温热病热入营血,壮热神昏,口干舌绛。生地黄中的成分可用热水进行提取。
当归流浸膏为历版《中国药典》收载,主要药效成分是水溶性的阿魏酸和脂溶性的藁本内酯。当归中的阿魏酸为有机酸类成分,易溶于热水、碱水,性质不够稳定,长时间加热会产生降解。所以可以用热水短时间加热进行提取。
红花黄色素在红花中含量占20%~30%,是含多种有效成分的水溶性成分,被认为红花的主要有效成分。将药物适当地切碎或粉碎成粗粉放入容器中,加水浸过药面,充分浸泡后,直火加热(不断搅拌以免药材局部受热,温度太高而焦糊,要注意红花吸水较多,在煎煮的过程中就要适当地加点水),煎煮、提取。
白芷,以根入药,有祛病除湿、排脓生肌、活血止痛等功能。主治风寒感冒、头痛、鼻炎、牙痛,主要为香豆素类成分。白芷中的成分可用热水进行提取。
杏仁是蔷薇科杏的种子,分为甜杏仁和苦杏仁,主要含有蛋白质、脂肪、糖、微量苦杏仁苷。脂肪的组成中主要是油酸和亚油酸。杏仁中的成分可用热水进行提取。
丹参,为唇形科植物丹参的干燥根和根茎。具有活血祛瘀,通经止痛,清心除烦,凉血消痈之功效。用于月经不调,痛经经闭,水溶性酚酸类成分如原儿茶醛、丹参素。丹参中的成分可用热水进行提取。
菟丝子,有补肝肾、益精壮阳及止泻的功能,菟丝子含生物碱、蒽醌、香豆素、黄酮,菟丝子中的成分可用热水进行提取。
黄精,具有补脾,润肺生津的作用。黄精的根状茎含甾体皂甙,已分离出2个呋甾烯醇型皂甙和2个螺甾烯醇型皂甙。黄精中的成分可用热水进行提取。
白及,为兰科植物白及的干燥块茎。用于皮肤皲裂,美白。白及主要成分有挥发油、生物碱、木脂素类酚酸性化合物等。白及中的成分可用热水进行提取。
月季花,为蔷薇科植物月季的干燥花。具有活血调经,疏肝解郁之功效。常用于气滞血瘀,月经不调,痛经,闭经,胸胁胀痛。主含挥发油,大部分为萜醇类化合物。月季花中的成分可用热水进行提取。
丁香,可以治疗改善衰弱体质与贫血,促进血液循环,治疗皮肤溃疡及伤口发炎,治疗疥癣,改善粗糙肌肤。花蕾含挥发油即丁香油。油中主要含有丁香油酚、乙酰丁香油酚、以及甲基正戊基酮、水杨酸甲酯。丁香中的成分可用热水进行提取。
白僵蚕,来源为蚕蛾科昆虫家蚕的幼虫感染白僵菌而僵死的干燥全虫。白僵蚕含有氨基酸和活性丝光素,有营养皮肤和美容作用。僵蚕所含蛋白质有刺激上皮脂腺,调节性激素分泌的作用,因而对女性性激素分泌失调引起的黄褐斑有一定疗效。白僵蚕蚕体中含有激素羟基促脱皮甾酮。体表的白粉中含有草酸铵、蛋白质和脂肪。白僵蚕中的成分可用热水进行提取。
2014年8月至2014年12月运用该组合物治疗皮肤光老化产生的黄褐斑和晒斑,并与西药组随机对比,疗效满意,报告如下:
1.临床资料根据参照中国中西医结合学会皮肤性病专业委员会色素病学纳入标准组制定的《黄褐斑的临床诊断和疗效标准》(年修订稿),选择符合标准并经中医辨证为气滞血瘀、痰浊瘀阻肌肤腠理,特别是经常进行室外活动的黄褐斑患者。
本研究共选病例均系西安海棠职业学院门诊患者,均为女性年龄患者。随机分为两组,治疗组30例平均20岁,病程2个月,平均1月为一个疗程,连续治疗两个疗程。对照组30例平均20岁,病程2个月,平均1月为一个疗程。连续治疗两个疗程。两组患者在年龄、病情严重程度等方面统计学处理无显著性差异具有可比性,本组60例患者均来自门诊,按就诊顺序的先后随机分为治疗组和对照组。治疗组和对照组在性别、年龄、病程、病情轻重及合并病等方面,经统计学处理,P>0.05。
2.治疗方法
治疗组给本申请组合物颗粒剂,每天2~3次,饭前30分钟服用。对照组给予维甲酸,由上山东良福制药有限公司生产,服法为第1周每天40毫克(早晚餐前20分钟各服20毫克);第2周,每天60毫克(早中晚餐前20分钟各服20毫克);第3周每天80毫克(早中餐前20分钟各服20毫克,晚餐前20分钟服40毫克);第4周递减剂量为每天60毫克。
服药期间,嘱两组患者治疗期间注意防晒,室外活动外涂防晒霜,停用其他诊断标准淡斑扶斑化妆品和药物。以1个月为1个疗程,所有病例观察时间均为2个疗程。
3.中西医证型诊断标准
3.1依照国家中医药管理局《中医病证诊断疗效标准》及文献资料,结合临床经验制定皮肤光老化黄褐斑标准如下:临床上主要表现为皮肤干燥、深皱纹、粗糙、皮革样、点状色素沉着或色素减退斑点、肤色灰黄。中医诊断五脏虚损、气血不足不能上荣于面、津液不布不足以滋润及痰浊瘀阻肌肤腠理。
3.2排除标准
①哺乳期和妊娠期妇女;②非肝瘀证型患者;③停服避孕药不足半年者;④心脑血管、肝、胃肠和造血系统等严重疾指数下降无效:肉眼视色斑面积消退颜色变化病者、精神病患者;⑤其他疾病(如黑变病、颧部褐青色色素性光化性扁平苔藓等)不明显引起的色素沉着;⑥未完成治疗和复诊者,无法判断疗效或资料不全者。
3.3纳入标准:
(1)女性;(2)20岁;(3)西安海棠职业学院新入学大学女生,喜欢户外活动并且军训后产生晒斑、黄褐斑的症状。
4.疗效分析
4.1评分方法
(1)根据皮损面积评分:无皮损:0分;皮损面积<2cm2:1分;皮损面积2~4cm2:2分;皮损面积>4cm2:3分。
(2)根据皮损颜色评分:正常肤色:0分;淡褐色:1分;褐色:2分;深褐色:3分。
总积分=面积积分+颜色积分。指数计算方法:指数=(治疗前总积分-治疗后总积分)/治疗前总积分。
4.2疗效标准
参照中国中西医结合学会皮肤性病专业委员会色素病学纳入标准组制定的《黄褐斑的临床诊断和疗效标准》(2003年修订稿)判定。
基本治愈:肉眼视色斑面积>90%,颜色基本消失,评分法治疗计算治疗后指数下降≥0.8;显效;
肉眼视色斑面积消退>60%,颜色明显变淡,评分法计算治疗后指数下降≥0.5;有效;
肉眼视色斑面积消退>30%,颜色变淡,评分法治疗后指数下降≥0.3;无效;
肉眼视色斑面积消退<30%,颜色变化不明显,评分法计算治疗后指数下降≤0。
总有效率=(痊愈+显效+有效)/总例数*100%。
5.治疗结果
5.1采用统计学软件SPSS15.0进行分析计数资料,采用X2检验,计量资料采用t检验,P<0.05为差异具有统计学意义。两组各30例完成观察,治疗组有效率为93.33%,对照组有效率为60.00%,X2=4.74,P<0.05。
表3治疗组与对照组疗效比较
组别 | n | 治愈 | 显效 | 有效 | 无效 | 有效率% |
治疗组 | 30 | 28 | 1 | 1 | 0 | 93.33 |
对照组 | 30 | 18 | 6 | 4 | 2 | 60.00 |
5.2症状积分比较
两组患者治疗前后积分比较,P<0.05。有统计学意义。
表4两组患者治疗前后积分比较
5.2不良反应
表5两组患者治疗前后不良反应对照表
组别 | 不良反应 |
治疗组 | 未出现因不良反应,治疗前后查血尿常规、心电图、肝肾功能均无异常。 |
对照组 | 部分患者出现恶心呕吐及食欲不振、头痛、头晕症状。 |
实施例1
按照质量百分比由以下中药饮片:生地6.004%、当归6.004%、红花6.004%、白芷8.285%、杏仁7.924%、丹参8.625%、菟丝子9.425%、黄精8.617%、白及10.00%、月季花10.00%、丁香10.00%、白僵蚕9.112%,净制,60℃以下干燥。
将称取的药材加入提取罐中,加水煎煮2次:第1次加饮片质量8倍的水,煎煮1.5h;第2次加饮片质量8倍的水,煎煮1h;药液滤过,滤液泵入药液贮罐,放置3h以上,取上清液滤过,得到提取液。
将提取液真空浓缩至相对密度1.02(80℃)浸膏,然后在真空干燥箱80℃,干燥50min,得到膏粉。将膏粉粉碎过80目筛。
将粉碎后的膏粉放入高效湿法混合制粒机中,加入辅料(蔗糖和麦芽糊精质量比1:1),膏粉与辅料的质量比为1:1,混合均匀,然后喷以质量浓度为85%的酒精作为粘合剂,酒精的用量为膏粉质量的15%,在48℃搅拌到手捏成团,触之即散时,过筛,整粒,放入烘箱中55℃干燥1.5h即得。
实施例2
按照质量百分比由以下中药饮片:生地10.00%、当归10.00%、红花10.00%、白芷6.004%、杏仁6.004%、丹参6.004%、菟丝子8.332%、黄精9.221%、白及7.013%、月季花8.267%、丁香9.432%、白僵蚕9.723%,净制,60℃以下干燥。
将称取的药材加入提取罐中,加水煎煮2次:第1次加饮片质量8倍的水,煎煮2h;第2次加饮片质量8倍的水,煎煮1.5h;药液滤过,滤液泵入药液贮罐,放置3h以上,取上清液滤过,得到提取液。
将提取液真空浓缩至相对密度1.04(80℃)浸膏,然后在真空干燥箱85℃,干燥60min,得到膏粉。将膏粉粉碎过80目筛。
将粉碎后的膏粉放入高效湿法混合制粒机中,加入辅料(蔗糖和麦芽糊精质量比1:1.5),膏粉与辅料的质量比为1:1.5,混合均匀,然后喷以质量浓度为90%的酒精作为粘合剂,酒精的用量为膏粉质量的20%,在55℃搅拌到手捏成团,触之即散时,过筛,整粒,放入烘箱中60℃干燥2h即得。
实施例3
按照质量百分比由以下中药饮片:生地8.785%、当归7.367%、红花6.983%、白芷10.00%、杏仁10.00%、丹参10.00%、菟丝子10.00%、黄精7.221%、白及8.482%、月季花7.125%、丁香7.559%、白僵蚕6.478%,净制,60℃以下干燥。
将称取的药材加入提取罐中,加水煎煮2次:第1次加饮片质量8倍的水,煎煮1.5h;第2次加饮片质量8倍的水,煎煮1.5h;药液滤过,滤液泵入药液贮罐,放置3h以上,取上清液滤过,得到提取液。
将提取液真空浓缩至相对密度1.03(80℃)浸膏,然后在真空干燥箱82℃,干燥55min,得到膏粉。将膏粉粉碎过80目筛。
将粉碎后的膏粉放入高效湿法混合制粒机中,加入辅料(蔗糖和麦芽糊精质量比1:1.2),膏粉与辅料的质量比为1:1.3,混合均匀,然后喷以质量浓度为88%的酒精作为粘合剂,酒精的用量为膏粉质量的17%,在50℃搅拌到手捏成团,触之即散时,过筛,整粒,放入烘箱中57℃干燥1.5h即得。
实施例4
按照质量百分比由以下中药饮片:生地7.756%、当归8.785%、红花8.521%、白芷9.075%、杏仁7.932%、丹参8.455%、菟丝子6.004%、黄精10.00%、白及6.004%、月季花9.464%、丁香8.004%、白僵蚕10.00%,净制,60℃以下干燥。
将称取的药材加入提取罐中,加水煎煮2次:第1次加饮片质量8倍的水,煎煮2h;第2次加饮片质量8倍的水,煎煮1h;药液滤过,滤液泵入药液贮罐,放置3h以上,取上清液滤过,得到提取液。
将提取液真空浓缩至相对密度1.02(80℃)浸膏,然后在真空干燥箱83℃,干燥52min,得到膏粉。将膏粉粉碎过80目筛。
将粉碎后的膏粉放入高效湿法混合制粒机中,加入辅料(蔗糖和麦芽糊精质量比1:1.1),膏粉与辅料的质量比为1:1.2,混合均匀,然后喷以质量浓度为89%的酒精作为粘合剂,酒精的用量为膏粉质量的16%,在52℃搅拌到手捏成团,触之即散时,过筛,整粒,放入烘箱中56℃干燥2h即得。
实施例5
按照质量百分比由以下中药饮片:生地9.529%、当归9.368%、红花9.734%、白芷8.926%、杏仁8.533%、丹参9.594%、菟丝子7.843%、黄精6.004%、白及9.637%、月季花6.004%、丁香8.824%、白僵蚕6.004%,净制,60℃以下干燥。
将称取的药材加入提取罐中,加水煎煮2次:第1次加饮片质量8倍的水,煎煮1.5h;第2次加饮片质量8倍的水,煎煮1.5h;药液滤过,滤液泵入药液贮罐,放置3h以上,取上清液滤过,得到提取液。
将提取液真空浓缩至相对密度1.04(80℃)浸膏,然后在真空干燥箱80~84℃,干燥57min,得到膏粉。将膏粉粉碎过80目筛。
将粉碎后的膏粉放入高效湿法混合制粒机中,加入辅料(蔗糖和麦芽糊精质量比1:1.4),膏粉与辅料的质量比为1:1.4,混合均匀,然后喷以质量浓度为87%的酒精作为粘合剂,酒精的用量为膏粉质量的19%,在54℃搅拌到手捏成团,触之即散时,过筛,整粒,放入烘箱中58℃干燥1.5h即得。
Claims (10)
1.具有活血、美容功效的中药组合物,其特征在于,按照质量百分比由以下中药组成:生地6.004%~10.00%、当归6.004%~10.00%、红花6.004%~10.00%、白芷6.004%~10.00%、杏仁6.004%~10.00%、丹参6.004%~10.00%、菟丝子6.004%~10.00%、黄精6.004%~10.00%、白及6.004%~10.00%、月季花6.004%~10.00%、丁香6.004%~10.00%、白僵蚕6.004%~10.00%,各组分的质量百分比之和为100%。
2.具有活血、美容功效的中药组合物颗粒剂的制备方法,其特征在于,具体按照以下步骤实施:
步骤1,分别称取生地、当归、红花、白芷、杏仁、丹参、菟丝子、黄精、白及、月季花、丁香、白僵蚕饮片;
步骤2,将步骤1称取的各原料饮片放入真空提取罐中,进行提取药液;
步骤3,将步骤2中提取的药液浓缩浸膏后,真空干燥,得到膏粉,并对膏粉进行粉碎过筛;
步骤4,将步骤3得到的膏粉放入高效湿法混合制粒机中,加入辅料,混合均匀,然后喷以粘合剂,搅拌、过筛、整粒、干燥,即得。
3.根据权利要求2所述的具有活血、美容功效的中药组合物颗粒剂的制备方法,其特征在于,所述步骤1中各原料饮片按照质量百分比分别为:地6.004%~10.00%、当归6.004%~10.00%、红花6.004%~10.00%、白芷6.004%~10.00%、杏仁6.004%~10.00%、丹参6.004%~10.00%、菟丝子6.004%~10.00%、黄精6.004%~10.00%、白及6.004%~10.00%、月季花6.004%~10.00%、丁香6.004%~10.00%、白僵蚕6.004%~10.00%,各组分的质量百分比之和为100%。
4.根据权利要求2所述的具有活血、美容功效的中药组合物颗粒剂的制备方法,其特征在于,所述步骤2中提取过程具体为:将称取的饮片加入真空提取罐中,加水煎煮2次,滤过,滤液泵入药液贮罐,放置3h以上,取上清液滤过,即得药液。
5.根据权利要求4所述的具有活血、美容功效的中药组合物颗粒剂的制备方法,其特征在于,所述2次煎煮具体为:第1次加饮片质量8倍的水,煎煮1.5~2h;第2次加饮片质量8倍的水,煎煮1~1.5h。
6.根据权利要求2所述的具有活血、美容功效的中药组合物颗粒剂的制备方法,其特征在于,所述步骤3中,浓缩后浸膏的相对密度1.02~1.04。
7.根据权利要求2所述的具有活血、美容功效的中药组合物颗粒剂的制备方法,其特征在于,所述步骤3中,真空干燥温度为80~85℃,干燥时间为50~60min;粉碎后过80目筛。
8.根据权利要求2所述的具有活血、美容功效的中药组合物颗粒剂的制备方法,其特征在于,所述步骤4中膏粉与辅料的质量比为1:1~1.5,辅料由蔗糖和麦芽糊精按质量比1:1~1.5组成。
9.根据权利要求2所述的具有活血、美容功效的中药组合物颗粒剂的制备方法,其特征在于,所述步骤4中酒精的质量浓度为85%~90%,酒精的用量为膏粉质量的15%~20%。
10.根据权利要求2所述的具有活血、美容功效的中药组合物颗粒剂的制备方法,其特征在于,所述步骤4中搅拌过程中控制温度在48~55℃;干燥温度为55~60℃,干燥时间为1.5~2h。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711237245.6A CN107875288A (zh) | 2017-11-30 | 2017-11-30 | 具有活血、美容功效的中药组合物及其颗粒剂的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711237245.6A CN107875288A (zh) | 2017-11-30 | 2017-11-30 | 具有活血、美容功效的中药组合物及其颗粒剂的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107875288A true CN107875288A (zh) | 2018-04-06 |
Family
ID=61776136
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711237245.6A Pending CN107875288A (zh) | 2017-11-30 | 2017-11-30 | 具有活血、美容功效的中药组合物及其颗粒剂的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107875288A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112618787A (zh) * | 2020-12-30 | 2021-04-09 | 广州小蛮腰医疗器械有限公司 | 一种皮下组织填充制剂及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102949668A (zh) * | 2012-11-14 | 2013-03-06 | 西安福安创意咨询有限责任公司 | 一种用于祛斑的保健品片剂及其制备方法 |
CN103751635A (zh) * | 2013-12-31 | 2014-04-30 | 青岛恒波仪器有限公司 | 一种治疗黄褐斑的中药面膜及其制备方法 |
-
2017
- 2017-11-30 CN CN201711237245.6A patent/CN107875288A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102949668A (zh) * | 2012-11-14 | 2013-03-06 | 西安福安创意咨询有限责任公司 | 一种用于祛斑的保健品片剂及其制备方法 |
CN103751635A (zh) * | 2013-12-31 | 2014-04-30 | 青岛恒波仪器有限公司 | 一种治疗黄褐斑的中药面膜及其制备方法 |
Non-Patent Citations (2)
Title |
---|
王媛: "防治"血瘀"光老化中药复方的研究", 《现代养生》 * |
王建军等: "活血美颗粒治疗日晒斑60例疗效观察", 《中国美容医学》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112618787A (zh) * | 2020-12-30 | 2021-04-09 | 广州小蛮腰医疗器械有限公司 | 一种皮下组织填充制剂及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100353983C (zh) | 一种降糖中药制剂 | |
CN108524814A (zh) | 一种用于降低血糖的中药组合物及其制备方法 | |
CN107549373A (zh) | 一种用于降血糖的保健茶、制备方法及应用 | |
CN1879601B (zh) | 乌发作用制剂的配方及制备方法 | |
CN106728898A (zh) | 一种修复皮肤屏障的药物组合物及其制备方法 | |
CN105497261A (zh) | 一种外用贴剂基质及该基质制成的外用贴剂和助眠贴 | |
CN101028325B (zh) | 一种含有塞隆骨的药物组合物及其制备方法和质量检测方法 | |
CN103566300B (zh) | 一种祛斑膏及其制备方法 | |
CN105055849A (zh) | 滋阴养肾的中药提取物及其制备方法和应用 | |
CN112089784A (zh) | 中药组合物在制备预防、治疗动脉粥样硬化所致疾病的药物中的应用 | |
CN103432412A (zh) | 一种治疗乳腺增生的药物及其制备方法 | |
CN107875288A (zh) | 具有活血、美容功效的中药组合物及其颗粒剂的制备方法 | |
CN102743539B (zh) | 一种温阳通脉治疗冠心病的中药及制备方法 | |
CN108310155A (zh) | 一种石墨烯乳腺增生治疗贴及其制作方法 | |
CN104324310A (zh) | 一种用于治疗免疫抑制后真菌性角膜炎的中药组合物及其制备方法 | |
CN101632813B (zh) | 新型的治疗糖尿病性眼底出血的中药组合物及其制备方法 | |
CN108403869B (zh) | 一种用于祛黄褐斑的中药组合物及其制备方法 | |
CN106729498A (zh) | 一种放化疗后食用的蛋白粉及其制备方法 | |
CN111888431A (zh) | 一种治疗糖尿病的组合物及其制备方法 | |
CN104474103A (zh) | 一种天然植物降糖剂及其制备方法 | |
CN108354879A (zh) | 一种祛痘防感染的面霜及其制备方法 | |
CN108853340A (zh) | 一种滋养肝肾的中药及其制备方法 | |
CN114712466B (zh) | 一种具有减肥养颜功效的药物及其制备方法 | |
CN107080811A (zh) | 治疗青春痘的中药制剂及其制备方法 | |
CN107551054A (zh) | 糖痹外洗方组合物、其制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180406 |